These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26893067)

  • 1. Signalling: Putting the brakes on KRAS-G12C nucleotide cycling.
    Shipman L
    Nat Rev Cancer; 2016 Mar; 16(3):127. PubMed ID: 26893067
    [No Abstract]   [Full Text] [Related]  

  • 2. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.
    Lito P; Solomon M; Li LS; Hansen R; Rosen N
    Science; 2016 Feb; 351(6273):604-8. PubMed ID: 26841430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
    Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
    Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS
    Xiao X; Lai M; Song Z; Geng M; Ding J; Xie H; Zhang A
    Eur J Med Chem; 2021 Mar; 213():113082. PubMed ID: 33309163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Kras
    Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
    J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
    Canon J; Rex K; Saiki AY; Mohr C; Cooke K; Bagal D; Gaida K; Holt T; Knutson CG; Koppada N; Lanman BA; Werner J; Rapaport AS; San Miguel T; Ortiz R; Osgood T; Sun JR; Zhu X; McCarter JD; Volak LP; Houk BE; Fakih MG; O'Neil BH; Price TJ; Falchook GS; Desai J; Kuo J; Govindan R; Hong DS; Ouyang W; Henary H; Arvedson T; Cee VJ; Lipford JR
    Nature; 2019 Nov; 575(7781):217-223. PubMed ID: 31666701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAS G12C Inhibitors: Three Birds with One Stone.
    Seale T; Misale S
    Cancer Discov; 2024 May; 14(5):698-700. PubMed ID: 38692265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
    Stites EC; Shaw AS
    CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the Clinical Development Candidate
    Fell JB; Fischer JP; Baer BR; Blake JF; Bouhana K; Briere DM; Brown KD; Burgess LE; Burns AC; Burkard MR; Chiang H; Chicarelli MJ; Cook AW; Gaudino JJ; Hallin J; Hanson L; Hartley DP; Hicken EJ; Hingorani GP; Hinklin RJ; Mejia MJ; Olson P; Otten JN; Rhodes SP; Rodriguez ME; Savechenkov P; Smith DJ; Sudhakar N; Sullivan FX; Tang TP; Vigers GP; Wollenberg L; Christensen JG; Marx MA
    J Med Chem; 2020 Jul; 63(13):6679-6693. PubMed ID: 32250617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the KRAS G12C mutation in patients with advanced solid tumors.
    Hong DS
    Clin Adv Hematol Oncol; 2019 Nov; 17(11):612-614. PubMed ID: 31851163
    [No Abstract]   [Full Text] [Related]  

  • 11. Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It's Down.
    Hobbs GA; Wittinghofer A; Der CJ
    Cancer Cell; 2016 Mar; 29(3):251-253. PubMed ID: 26977877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring Targeted Degradation Strategy for Oncogenic KRAS
    Zeng M; Xiong Y; Safaee N; Nowak RP; Donovan KA; Yuan CJ; Nabet B; Gero TW; Feru F; Li L; Gondi S; Ombelets LJ; Quan C; Jänne PA; Kostic M; Scott DA; Westover KD; Fischer ES; Gray NS
    Cell Chem Biol; 2020 Jan; 27(1):19-31.e6. PubMed ID: 31883964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dueling KRAS
    Cancer Discov; 2020 Jan; 10(1):10. PubMed ID: 31822538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents.
    Li L; Zhao H; Liao H; Chen J; Liu J; Chen J
    Bioorg Chem; 2021 May; 110():104825. PubMed ID: 33774492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct KRAS inhibition: progress, challenges, and a glimpse into the future.
    Grapsa D; Syrigos K
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):437-440. PubMed ID: 32320301
    [No Abstract]   [Full Text] [Related]  

  • 16. After decades, progress against an 'undruggable' cancer target.
    Kaiser J
    Science; 2019 Nov; 366(6465):561. PubMed ID: 31672875
    [No Abstract]   [Full Text] [Related]  

  • 17. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
    Nyíri K; Koppány G; Vértessy BG
    Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonclinical Safety Profile of Sotorasib, a KRAS
    Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
    Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting mutant KRAS.
    Erlanson DA; Webster KR
    Curr Opin Chem Biol; 2021 Jun; 62():101-108. PubMed ID: 33838397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
    Chen H; Smaill JB; Liu T; Ding K; Lu X
    J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.